Consultant in General Paediatrics and Vaccinology, Honorary Senior Clinical Lecturer, Group Head / PI, Consultant Physician and Member of congregation
Dr Matthew Snape, MBBS FRCPCH MD, is a Consultant in General Paediatrics and Vaccinology at the NIHR Oxford Biomedical Research Council and the Children’s Hospital Oxford, Oxford University Hospitals NHS Trust. He is also an Honorary Senior Clinical Lecturer at the Department of Paediatrics, University of Oxford, a Jenner Investigator and a fellow of St Cross College, Oxford.
Dr Snape's principal areas of research relate to vaccines against meningococcal, pneumococcal, and influenza, and prevention of disease through maternal immunisation. In 2014/2015 he was the lead investigator on a 'first in human' phase 1 study of a candidate ebola vaccine, providing data crucial to the planning of subsequent studies in West Africa.
Dr Snape graduated from the University of Melbourne in 1993 and completed his basic paediatric training at the Royal Children’s Hospital, Melbourne before continuing his training at St Mary’s Hospital, London. While working in the Paediatric Intensive Care Unit at St Mary’s hospital he became interested in the prevention of invasive meningococcal disease by immunisation, and on completion of his clinical training took up a post as a research fellow (later Clinical Lecturer) at the Oxford Vaccine Group, University of Oxford. While here he completed his post- graduate Doctor of Medicine (MD) degree, awarded by the University of Melbourne in 2009. He has been employed as a Consultant in Geenza and ebola disease, and prevention of disease through maternal immunisation.
Dr Snape was acknowledged as an NIHR Clinical Research Network ‘Leading Commercial Principal Investigator’ in 2015 by Dame Sally Davis, Chief Medical Office, and has published over 70 manuscripts relating to immunisation. He is also a member of the Meningitis Research Foundation's Medical Advisory Group.
Dr Snape is an Academic Training Programme Director for Oxford University Clinical Academic Graduate School (OUCAGS), with a particular focus on paediatric academic training.
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Liu X. et al, (2021), Lancet
SARS-CoV-2 Variants and Vaccines.
Krause PR. et al, (2021), The New England journal of medicine
T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire.
Swanson PA. et al, (2021), medRxiv
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116